Viridian Therapeutics (VRDN)

Executive Summary

Viridian Therapeutics is a clinical-stage biotechnology company focused on developing optimized monoclonal antibody treatments for rare autoimmune diseases, with a primary emphasis on Thyroid Eye Disease (TED). Leveraging its proprietary FcRn inhibition platform, the company aims to address significant unmet medical needs by delivering therapies with improved efficacy and convenience. Viridian's lead product candidates, VRDN-001 and VRDN-003, are designed to target the underlying pathophysiology of TED, a debilitating condition with limited treatment options. The company completed key Phase 3 trials for VRDN-001 in 2025 and is currently advancing multiple Phase 3 studies for VRDN-003, a next-generation antibody with a potentially more favorable dosing profile. In the near term, Viridian's most critical catalysts include the completion of three active Phase 3 trials for VRDN-003 in TED, with top-line data expected in the second half of 2026. These trials (NCT06625411, NCT06625398, NCT06812325) are evaluating the efficacy and safety of subcutaneous VRDN-003 against placebo. Positive results could support a regulatory filing for VRDN-003 in 2027, offering a differentiated treatment option. Additionally, the company may announce plans for a Biologics License Application (BLA) for VRDN-001 based on its completed THRIVE trial data. Successful execution of these milestones could significantly expand Viridian's commercial footprint and validate its platform in the TED market.

Upcoming Catalysts (preview)

• Q4 2026VRDN-003 Phase 3 Top-Line Data Readout (THRIVE-2 and related trials)65% success
• H2 2026BLA Submission for VRDN-001 in Thyroid Eye Disease80% success
• H1 2027Initiation of Phase 2/3 Trial for VRDN-003 in Chronic/TED Maintenance75% success